Loading...

ALT ALTIMMUNE INC Capital Structure Changes 8-K Filing

LTMM

LT

ALTIMMUNE INC

(ALT)

2026 8-K

Financial Results Report

Annual Meeting Announcement

Funding Announcement

Positive Trial Results

Management Transition

New Equity Offering

Loan Agreement Update

Management Change

Annual Meeting Results

Clinical Trials

Debt-Equity Swaps

New Indications

Management Change

Board Appointments

Financial Results

CFO Appointment

Annual Meeting Results

Earnings Reports

Appointment of Acting CFO

Earnings Reports

Financial Results and Obesi...

Obesity trial results

Earnings Reports

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Appointment of Director

Earnings Reports

External Links:

On January 27, 2026, Altimmune, Inc. entered into a Securities Purchase Agreement to issue 12.4 million shares and pre-funded warrants to raise approximately $75 million. This offering is set to close on January 29, 2026, contingent on standard closing conditions.

AI Assistant

ALTIMMUNE INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.